LAST WEEK TODAY!

A summary of what was published on ProstateWarriors.com during the past week

Hi fellow warriors! We’ve reached Newsletter number 26, exactly halfway through the year, and once again, we have positive updates from both clinical and preclinical research. Notably, 3 out of 4 clinical trials this week are about radiopharmaceuticals. Stay strong and fight on!

As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE.​

Clinical Research

• 225Ac-LNC1011: A New Alpha Therapy for PSMA-Positive mCRPC​
  A Phase 1 clinical trial conducted in China investigated 225Ac-LNC1011, a novel alpha emitter therapy for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). Among the four patients treated, the objective response rate (ORR) was 50% based on RECIST v1.1, and 75% using PET-based PERCIST v1.0. All patients experienced significant reductions in PSA levels—for example, one dropped from 7.885 ng/mL to 0.185 ng/mL. Median progression-free survival had not yet been reached, and three patients showed improved ECOG performance scores. The side effects were mild and manageable.
  ​
• Cu-61 NuriPro: Next-Generation PSMA Imaging Agent
  ​Cu-61 NuriPro is a new PET imaging agent evaluated in a Phase 1 trial for patients with PSMA-positive metastatic prostate cancer. The trial, presented at the 2025 SNMMI meeting, showed that Cu-61 NuriPro detected more lesions than the commonly used F-18 piflufolastat in 50% of patients. It also delivered high-quality images up to four hours post-injection thanks to copper-61’s favorable half-life and high positron yield. The agent demonstrated a safety profile comparable to existing tracers, and researchers plan to develop a therapeutic version, Cu-67 NuriPro, which is expected to enter clinical trials in 2026.​
  ​
• 225Ac-ETN029: A New Option for Neuroendocrine Prostate Cancer​
  The alpha-emitting therapy 225Ac-ETN029 is being tested in a Phase 1 trial for neuroendocrine prostate cancer (NEPC), a rare and aggressive prostate cancer subtype. This therapy targets DLL3, a protein expressed in approximately 77% of NEPC tumors. The study aims to recruit 65 patients with advanced DLL3-positive solid tumors, including both de novo and treatment-emergent NEPC. The approach promises high precision and minimal off-target effects.
  ​
• WGc-043: Investigating an mRNA Vaccine for EBV-Linked Prostate Cancer​
  WGc-043 is a novel mRNA cancer vaccine being tested in a Phase 1 clinical trial for patients with Epstein-Barr virus (EBV)-positive solid tumors, including prostate cancer. Approved by the FDA for investigational use, this vaccine aims to stimulate an immune response against EBV-related cancer cells. The study will enroll 64 patients and is designed to assess safety, tolerability, and initial antitumor activity. Although not yet recruiting, the trial is built on research suggesting EBV may contribute to prostate cancer development, especially in more advanced stages. WGc-043 has shown promise in other EBV-associated cancers, though its role in prostate cancer remains in early exploration.
  ​

Preclinical Research

• AlphaGenome: DeepMind’s Next Leap in Biological AI​
  AlphaGenome is the latest AI tool from DeepMind, following AlphaFold 2 and AlphaFold 3, and represents a major advance in understanding gene regulation. While AlphaFold 2 revolutionized biology by predicting protein 3D structures, and AlphaFold 3 expanded this to include DNA, RNA, and drug interactions, AlphaGenome goes deeper into how genes are turned on and off. It predicts the function of regulatory DNA elements, offering critical insights into diseases caused by misregulated gene expression. By decoding the functional “grammar” of the genome, AlphaGenome supports breakthroughs in gene therapy, personalized medicine, and the simulation of complex biological experiments in silico, saving time and costs in research.
  ​
• In-Body CAR T Cell Production Using Nanoparticles​
  A groundbreaking method reported in Science (June 2025) describes the creation of CAR T cells directly inside the human body using targeted lipid nanoparticles (tLNPs). These nanoparticles are designed with a lipid called L829 to avoid liver uptake and selectively deliver mRNA to CD5-expressing T cells. Once inside, the mRNA programs T cells to express chimeric antigen receptors (CARs), enabling them to attack cancer cells without needing permanent genetic modification. In preclinical tests, these engineered T cells cleared tumors in leukemia mouse models after multiple doses. This approach could transform CAR T cell therapy by making it faster, cheaper, and more accessible, though human trials are still needed.
  ​
• DiWB-1: A Dual-Target Strategy for Resistant Prostate Cancer​
  DiWB-1 is an emerging peptide-drug conjugate (PDC) designed to treat resistant forms of prostate cancer. It combines a luteinizing hormone-releasing hormone (LHRH)-targeting peptide with a PI3K inhibitor, exploiting the overexpression of LHRH receptors on prostate cancer cells. The drug specifically disrupts the PI3K/AKT/mTOR pathway, a critical survival mechanism in castration-resistant prostate cancer (CRPC), particularly in cases that no longer respond to androgen deprivation therapy. By targeting delivery to tumor cells, DiWB-1 aims to minimize systemic toxicity and improve treatment outcomes. Preclinical models suggest significant tumor reduction with fewer side effects compared to non-targeted PI3K inhibitors.
  ​
  ​

And…that’s all folks! For today at least!
Please let me know if there is anything I can improve in my newsletters, and let me know if you have enjoyed the podcast.

If you this newsletter was delivered to your SPAM folder, make sure to let your email system know that it is not spam.
​
​
Have a great weekend!

Max